Business Wire06.01.16
Inogen Inc., a medical technology company offering respiratory products for use in the homecare setting, has released its Inogen One G4 portable oxygen concentrator. The ultra-portable device is the smallest and lightest oxygen concentrator ever produced by the company, and executives predict the product will be embraced by long-term oxygen therapy users worldwide.
At 2.8 pounds, the Inogen One G4 is small and light-weight, allowing it to seamlessly fit into the lifestyles of active oxygen therapy patients. Compared to the popular Inogen One G3, the Inogen One G4 is more than 40 percent lighter and is approximately half the size. Weighing less than commonly used oxygen tanks, the Inogen One G4 can easily be carried over the shoulder, worn on the hip or belt, or carried in a convenient backpack with optional accessories. With three flow settings and Inogen’s standard intelligent delivery technology, the Inogen One G4 was designed to meet the clinical needs of more than 85 percent of patients that express an interest in the company’s products as a single solution for oxygen therapy—at home, away, and for travel. Other patient-preferred features include a long battery life of up to six hours with the optional double battery, a large LCD screen, and very quiet operation.
The Inogen One G4 represents a step forward in innovation within the oxygen therapy market, company executives claim. Management believes the Inogen One G4 boasts the highest oxygen output per pound of weight of any oxygen concentrator currently available in the supplemental oxygen therapy U.S. homecare market.
“The Inogen One G4 exemplifies Inogen’s spirit of innovation and dedication to designing products specifically for the end consumer, the oxygen therapy user,” said Raymond Huggenberger, Inogen’s CEO. “We are extremely proud of the level of innovation that we are delivering to patients, and we look forward to hearing about the lives changed because of the Inogen One G4.”
The Inogen One G4 has been released for sale to oxygen therapy patients in the company’s direct-to-consumer sales channel and is expected to be made available to additional sales channels, including domestic and international business-to-business channels (pending receipt of any required foreign regulatory approvals), through a controlled rollout process over the coming months.
In addition, on May 24, 2016, the U.S. Department of Transportation and Federal Aviation Administration (FAA) published a final rule concerning the acceptance criteria for portable oxygen concentrators used on board aircraft. The final rule replaces the current product by product approval process and allows commercial aircraft passengers to use a portable oxygen concentrator on board if the portable concentrator satisfies certain acceptance criteria and the product has a label indicating conformance with the acceptance criteria. The Inogen One G4 satisfies the necessary acceptance criteria; therefore the expected date that passengers will be able to travel on board commercial aircraft with the Inogen One G4 is the final rule implementation date, or August 22. In the meantime, Inogen One G4 users are encouraged to contact the company if they wish to travel via commercial aircraft to discuss options for traveling with the Inogen One G3 that is currently approved by the FAA.
Additional specifications for the Inogen One G4 can be found below:
*At flow setting 2
Inogen is based in Goleta, Calif.
At 2.8 pounds, the Inogen One G4 is small and light-weight, allowing it to seamlessly fit into the lifestyles of active oxygen therapy patients. Compared to the popular Inogen One G3, the Inogen One G4 is more than 40 percent lighter and is approximately half the size. Weighing less than commonly used oxygen tanks, the Inogen One G4 can easily be carried over the shoulder, worn on the hip or belt, or carried in a convenient backpack with optional accessories. With three flow settings and Inogen’s standard intelligent delivery technology, the Inogen One G4 was designed to meet the clinical needs of more than 85 percent of patients that express an interest in the company’s products as a single solution for oxygen therapy—at home, away, and for travel. Other patient-preferred features include a long battery life of up to six hours with the optional double battery, a large LCD screen, and very quiet operation.
The Inogen One G4 represents a step forward in innovation within the oxygen therapy market, company executives claim. Management believes the Inogen One G4 boasts the highest oxygen output per pound of weight of any oxygen concentrator currently available in the supplemental oxygen therapy U.S. homecare market.
“The Inogen One G4 exemplifies Inogen’s spirit of innovation and dedication to designing products specifically for the end consumer, the oxygen therapy user,” said Raymond Huggenberger, Inogen’s CEO. “We are extremely proud of the level of innovation that we are delivering to patients, and we look forward to hearing about the lives changed because of the Inogen One G4.”
The Inogen One G4 has been released for sale to oxygen therapy patients in the company’s direct-to-consumer sales channel and is expected to be made available to additional sales channels, including domestic and international business-to-business channels (pending receipt of any required foreign regulatory approvals), through a controlled rollout process over the coming months.
In addition, on May 24, 2016, the U.S. Department of Transportation and Federal Aviation Administration (FAA) published a final rule concerning the acceptance criteria for portable oxygen concentrators used on board aircraft. The final rule replaces the current product by product approval process and allows commercial aircraft passengers to use a portable oxygen concentrator on board if the portable concentrator satisfies certain acceptance criteria and the product has a label indicating conformance with the acceptance criteria. The Inogen One G4 satisfies the necessary acceptance criteria; therefore the expected date that passengers will be able to travel on board commercial aircraft with the Inogen One G4 is the final rule implementation date, or August 22. In the meantime, Inogen One G4 users are encouraged to contact the company if they wish to travel via commercial aircraft to discuss options for traveling with the Inogen One G3 that is currently approved by the FAA.
Additional specifications for the Inogen One G4 can be found below:
- Weight: 2.8 lbs. (includes single battery)
- Size: Length - 5.91 in., width - 2.68 in., height - 7.2 in. (includes single battery)
- Oxygen flow: Pulse dose delivery system with three flow settings
- Power: AC power supply, 100-240 volts, 50-60 Hz (auto sensing to allow worldwide use)
- Battery: Duration (single battery) - up to three hours; recharge up to 3.25 hours with AC or DC power; Duration (double battery) - up to six hours, recharge up to six hours with AC or DC power
- Noise level: 40 dBA*
- Operation: Simple control functions and easy-to-read LCD display
- Use: Designed for continuous 24/7 use
*At flow setting 2
Inogen is based in Goleta, Calif.